Bioequivalence study of dapagliflozin + metformin versus XIGDUO XR in healthy Thai adults under fed conditions

Phase 1, randomised, open-label trial of dapagliflozin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dr. Sasitorn Kittivoravitkul. Primary endpoints: Maximum plasma concentration (Cmax) of dapagliflozin and metformin at 72.00 hours, Area under the plasma concentration-time curve from dosing to last observed concentration (AUC0-t) of dapagliflozin and metformin at 72.00 hours and 1 more. Planned start Nov 2026; status: not yet recruiting.